Molecular targets of HEPV oncoproteins: Potential biomarkers for cervical carcinogenesis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 91-103

  De Freitas, Antonio Carlos ^a   Coimbra, Eliane Campos ^a   Leitão, Maria da Conceição Gomes ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Biomarkers; Cervical cancer; HPV; Oncoproteins

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; CELL SURFACE RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; DNA TOPOISOMERASE (ATP HYDROLYSING); E5 ONCOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MICRORNA; MINICHROMOSOME MAINTENANCE PROTEIN 2; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VASCULOTROPIN; TUMOR MARKER;

CANCER PROGNOSIS; CANCER SCREENING; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VIRUS CARCINOGENESIS; WART VIRUS; CARCINOGENESIS; FEMALE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; ONCOPROTEINS; PAPILLOMA VIRUS; PATHOGENICITY; PATHOLOGY; PRECANCER; UTERINE CERVIX TUMOR;

BIOMARKERS; CERVICAL CANCER; HPV; ONCOPROTEINS;

CARCINOGENESIS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS; PAPILLOMAVIRIDAE; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84892957649     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.12.004     Document Type: Review

References (255)

1. Parkin D.M. The global health burden of infection-associated cancers in the year. Int. J. Cancer 2006, 118:3030-3044.
2. Lowndes C.M. Vaccines for cervical cancer. Epidemiol. Infect. 2006, 134:1-12.
3. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World Summary Report 2010, (Available at http://www.who.int/hpvcentre, accessed 17 March 2013).
4. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 2004, 4:46-54.
5. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.
6. Bosh F.X., de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J. Natl. Cancer Inst. Monogr. 2003, 31:3-13.
7. Munoz N., Castellsague X., de Gonzalez A.B., Gissmanl L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24:1-10.
8. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., Hausen Hz., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
9. Derchain S.F.M., Longatto Filho A., Syrjanen K.J. Neoplasia intra-epitelial cervical: diagnóstico e tratamento. Rev. Bras. Ginecol. Obstet. 2005, 27:425-433.
10. Pinto A.P., Degen M., Villa L.L., Cibas E.S. Immunomarkers in gynecologic cytology: the search for the ideal biomolecular Papanicolaou test. Acta Cytol. 2012, 56:109-121.
11. Hausen H.Z. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 2000, 92:690-698.
12. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., Garcia F.A., Moriarty A.T., Waxman A.G., Wilbur D.C., Wentzensen N., Downs L.S., Spitzer M., Moscicki A.B., Franco E.L., Stoler M.H., Schiffman M., Castle P.E., Myers E.R. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee, American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 2012, 62:147-172.
13. Ronco G., Segnan N., Giorgi-Rossi P., Zappa M., Casadei G.P., Carozzi F., Dalla Palma P., Del Mistro A., Folicaldi S., Gillio-Tos A., Nardo G., Naldoni C., Schincaglia P., Zorzi M., Confortini M., Cuzick J. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl. Cancer Inst. 2006, 98:765-774.
14. Stanley M. Genital human papillomavirus infection-current and prospective therapies. J. Natl. Cancer Inst. Monogr. 2003, 31:117-124.
15. Brown C.A., Bogers J., Sahebali S., Depuydt C.E., De Prins F., Malinowski D.P. Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs. J. Oncol. 2012, 28:1-11.
16. Baldwin P., Laskey R., Coleman N. Translational approaches to improving cervical screening. Nat. Rev. Cancer 2003, 3:217-226.
17. Beccati M.D., Buriani C., Pedriali M., Rossi S., Nenci I. Quantitative detection of molecular markers ProEx C (minichromosome maintenance protein 2 and topoisomerase IIa) and MIB-1 in liquid-based cervical squamous cell cytology. Cancer 2008, 114:196-203.
18. Sung C.O., Kim S.R., Oh Y.L., Song S.Y. The use of p16 INK4A immunocytochemistry in 'Atypical squamous cells which cannot exclude HSIL' compared with 'Atypical squamous cells of undetermined significance' in liquid-based cervical smears. Diagn. Cytopathol. 2010, 38:168-171.
19. Pinto A.P., Crum C.P., Hirsch M.S. Molecular markers of early cervical neoplasia. Diagn. Histopathol. 2010, 16:445-454.
20. Nasioutziki M., Daniilidis A., Dinas K., Kyrgiou M., Valasoulis G., Loufopoulos P.D., Para-skevaidis E., Loufopoulos A., Karakitsos P. The evaluation of p16INK4a immune expression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int. J. Gynecol. Cancer 2011, 21:79-85.
21. Lee J.W., Choi C.H., Choi J.J., Park Y.A., Kim S.J., Hwang S.Y., Kim W.Y., Lee J.H., Kim B.G., Bae D.S. Altered MicroRNA expression in cervical carcinomas. Clin. Cancer Res. 2008, 14:2535-2542.
22. Wang X., Wang H.K., McCoy J.P., Banerjee N.S., Rader J.S., Broker T.R., Meyers C., Chow L.T., Zheng Z.M. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009, 15:637-647.
23. Pereira P.M., Marques J.P., Soares A.R., Carreto L., Santos M.A. MicroRNA expression variability in human cervical tissues. PLoS One 2010, 5:e11780.
24. Rao Q., Zhou H., Peng Y., Li J., Lin Z. Aberrant MicroRNA expression in human cervical carcinomas. Med. Oncol. 2012, 29:1242-1248.
25. Zheng Z.M., Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim. Biophys. Acta 2011, 1809:668-677.
26. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
27. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756.
28. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
29. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
30. Bader A.G., Lammers P.L. The Therapeutic Potential of microRNAs. Innov. Pharm. Technol. 2011, 52-55. (March Issue).
31. Haller K., Stubenrauch F., Pfister H. Differentiation-dependent transcription of the epidermodysplasia verruciformis-associated human papillomavirus type 5 in benign lesions. Virology 1995, 214:245-255.
32. McLaughlin-Drubin M.E., Munger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009, 143:195-208.
33. Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. Faseb J. 1993, 7:872-879.
34. Sandal T. Molecular aspects of the mammalian cell cycle and cancer. Oncologist 2002, 7:73-81.
35. Jayshree R.S., Sreenivas A., Tessy M., Krishna S. Cell intrinsic & extrinsic factors in cervical carcinogenesis. Indian J. Med. Res. 2009, 130:286-295.
36. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 2010, 10:550-560.
37. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
38. Eichten A.D.S., Rud M., Grace S.O., Piboonniyom V., Zacny V., Münger K. Molecular pathways executing the "trophic sentinel" response in HPV-16 E7-expressing normal human diploid fibroblasts upon growth factor deprivation. Virology 2004, 319:81-93.
39. Finzer P., Aguilar-Lemarroy A., Rosl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 2002, 188:15-24.
40. Motoyama S., Ladnines-Llave C.A., Villanueva S.L., Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J. Med. Sci. 2004, 50:9-19.
41. Ueda Y., Enomoto T., Miyatake T., Ozaki K., Yoshizaki T., Kanao H., Ueno Y., Nakashima R., Shroyer K., Murata Y. Monoclonal expansion with integration of high-risk type human papillomaviruses is an initial step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab. Investig. 2003, 83:1517-1527.
42. Bosch F.X., Muñoz N., Shah K.V., Meheus A. Second International Workshop on the epidemiology of cervical cancer and human papillomavirus. Int. J. Cancer 1992, 52:171-173.
43. Jeon S., Allen-Hoffmann B.L., Lambert P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 1995, 69:2989-2997.
44. Doorbar J. The papillomavirus life cycle. J. Clin. Virol. 2005, 32:7-15.
45. Duensing S., Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002, 62:7075-7082.
46. Duensing A., Liu Y., Perdreau S.A., Klevlein-Sohn J., Nigg E.A., Duensing S. Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates. Oncogene 2007, 26:6280-6288.
47. Garnett T.O., Filippova M., Duerksen-Hughes P.J. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ. 2006, 13:1915-1926.
48. Garnett T.O., Duerksen-Hughes P.J. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch. Virol. 2006, 151:2321-2335.
49. Storey D., Pim D., Murray A., Osborn K., Banks L., Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. Embo J. 1988, 7:1815-1820.
50. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79.
51. Dimaio D., Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 2001, 20:7866-7873.
52. Venuti A., Salani D., Poggiali F., Manni V., Bagnato A. The E5 oncoprotein of human papillomavirus type 16 enhances endothelin-1-induced keratinocyte growth. Virology 1998, 248:1-5.
53. Oh J.M., Kim S.H., Lee Y.I., Seo M., Kim S.Y., Song Y.S., Kim W.H., Juhnn Y.S. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 2009, 30:141-149.
54. Pedroza-Saavedra E.W., Lam F., Esquivel-Guadarrama L. Gutierrez-Xicotencatl, The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1). Virology 2010, 400:44-52.
55. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J. Clin. Oncol. 2005, 23:254-266.
56. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M., Croce CM C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2999-3004.
57. Lajer C.B., Garnæs E., Friis-Hansen L., Norrild B., Therkildsen M.H., Glud M., Rossing M., Lajer H., Svane D., Skotte L., Specht L., Buchwald C., Nielsen F.C. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br. J. Cancer 2012, 106:1526-1534.
58. Reshmi G., Radhakrishna Pillai M. Interplay Between HPV Oncoproteins and MicroRNAs in Cervical Cancer book. Published: January 25, 2012 under CC BY 3.0 license Chapter 14 Interplay Between HPV Oncoproteins and MicroRNAs in Cervical Cancer 2012, 10.5772/29866. D. Vanden Broeck (Ed.).
59. Greco N., Kivi K., Qian S.K., Leivonen P., Auvinen E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 2011, 6:e21646.
60. Rajkumar T., Sabitha K., Vijayalakshmi N., Shirley S., Bose M.V., Gopal G., Selvaluxmy G. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 2011, 11:1-14.
61. wang S.J., Shroyer K.R. Biomarkers of cervical dysplasia and carcinoma. J. Oncol. 2012, 1-9.
62. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63:4417-4421.
63. Sano T., Oyama T., Kashiwabara K., Fukuda T., Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am. J. Pathol. 1998, 153:1741-1748.
64. Bouvard V., Matlashewski G., Gu Z.M., Storey A., Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 1994, 203:73-80.
65. Williams S.M.G., Disbrow G.L., Schlegel R., Lee D., Threadgill D.W., Lambert P.F. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogenes. Cancer Res. 2005, 65:6534-6542.
66. Suprynowicz F.A., Campo M.S., Schlegel R. Biological activitites of papillomavirus E5 proteins. Papillomavirus Research: From Natural History to Vaccines and Beyond 2006, 97-113. Caister Academic Press, Wymondham, United Kingdom. M.S. Campo (Ed.).
67. Sahab Z., Sudarshan S.R., Liu X., Zhang Y., Kirilyuk A., Kamonjoh C.M., Simic V., Dai Y., Byers S.W., Doorbar J., Suprynowicz F.A., Schlegel R. Quantitative measurement of human papillomavirus type 16 E5 oncoprotein levels in epithelial cell lines by mass spectrometry. J. Virol. 2012, 86:9465-9947.
68. Choo K.B., Pan C.C., Liu M.S., Han S.H., Ng H.T., Chen C.P., Lee Y.N., Chao C.F., Meng C.L., Yeh M.Y. Presence of episomal and integrated human papilomavirus DNA sequences in cervical carcinoma. J. Med. Virol. 1987, 21:101-107.
69. Cullen A.P., Reid R., Campion M., Lorincz A.T. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 1991, 65:606-612.
70. Chang J.L., Tsao Y.P., Liu D.W., Huang S.J., Lee W.H., Chen S.L. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J. Biomed. Sci. 2001, 8:206-213.
71. Hafner N., Driesch C., Gajda M., Jansen L., Kirchmayr R., Runnebaum I.B., Dürst M. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008, 27:1610-1617.
72. Koh J., Enders G.H., Dynlacht B.D., Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995, 375:506-510.
73. Khleif S.N., Degregori J., Yee C.L., Otterson G.A., Kaye F.J., Nevins J.R., Howley P.M. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:4350-4354.
74. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., Hellweg G.D., Schmidt D., Doeberitz M.V.K. Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 2001, 92:276-284.
75. Nieh S., Chen S.F., Chu T.Y., Lai H.C., Fu E. Expression of p16INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol. Oncol. 2003, 91:201-208.
76. Guo M., Hu L., Baliga M., He Z., Hughson M.D. The predictive value of p16INK4a and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol. 2004, 122:894-901.
77. Nieh S., Chen S.F., Chu T.Y., Lai H.C., Fu E., Gau C.H. Is p16INK4A expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol. Oncol. 2005, 97:35-40.
78. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 2000, 182:311-322.
79. Kruse A.J., Baak J.P.A., Janssen E.A., Kjellevold K.H., Fiane B., Lovslett K., Bergh J., Robboy S. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell. Oncol. 2004, 26:13-20.
80. Baak J.P., Kruse A.J., Robboy S.J., Janssen E.A., Diermen B.V., Skaland I. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J. Clin. Pathol. 2006, 59:1017-1028.
81. Kruse A.J., Baak J.P., de Bruin P.C., Jiwa M., Snijders W.P., Boodt P.J., Fons G., Houben P.W. H. S. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J. Pathol. 2001, 193:48-54.
82. Santin A.D., Zhan F., Bignotti E., Siegelc R.E., Canéa S., Bellonea S., Palmieria M., Anfossia S., Thomas M., Burnetta A., Kaye H.H., Romana J.J., O'Briena T.J., Tianb E., Cannonf M.J., Shaughnessy J., Pecorellig S. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005, 331:269-291.
83. Malinowski D.P. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques 2005, 38:S17-S23.
84. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 1987, 56:881-914.
85. Carpenter G., Wahl M.I. The epidermal growth factor family. Peptide Growth Factors and their Receptors 1990, 69-171. Springer-Verlag, Berlin. M.B. Sporn, A.B. Roberts (Eds.).
86. Straight S.W., Herman B., McCance D.J. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 1995, 69:3185-3192.
87. Crusius K., Auvinen E., Steuer B., Gaissert H., Alonso A. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp. Cell Res. 1998, 241:76-83.
88. Chell S.D., Witherden I.R., Dobson R.R., Moorghen M., Herman A.A., Qualtrough D., Williams A.C., Paraskeva C. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res. 2006, 66:3106-3113.
89. Kim M.K., Kim H.S., Kim S.H., Oh J.M., Han J.Y., Lim J.M., Juhnn Y.S., Song Y.S. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem. Pharmacol. 2010, 80:1930-1935.
90. Tsao Y.P., Li L.Y., Tsai T.C., Chen S.L. Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratino-cytes. J. Virol. 1996, 70:7535-7539.
91. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
92. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulated carcinoma growth. J. Clin. Investig. 2000, 105:1589-1594.
93. Elder D.J., Halton D.E., Hague A., Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 1997, 3:1679-1683.
94. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60:1306-1311.
95. Kang H.J., Gong G., Jang S.J., Jung P.J., Park C.K. Expression of cyclooxygenase-2 in human breast carcinoma: relevance to tumor angiogenesis and expression of estrogen receptor. Cancer Res. Treat. 2001, 33:286-295.
96. Byrne A.M., Bouchier-Hayes D.J., Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell. Mol. Med. 2005, 9:777-794.
97. Kim S.H., Juhnn Y.S., Kang S., Park S.W., Sung M.W., Bang Y.J. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor MEK/ERK1,2 and PI3K/Akt. Cell. Mol. Life Sci. 2006, 63:930-938.
98. Kim S.H., Oh J.M., No J.H., Bang Y.J., Juhnn Y.S., Song Y.S. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009, 30:753-757.
99. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
100. Parton R.G. Caveolae and caveolins. Curr. Opin. Cell Biol. 1996, 8:542-548.
101. Smart E.J., Graf1 A.G., McNiven M.A., Sessa W.C., Engelman J.A., Scherer P.E., Okamoto T., Lisanti M.P. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 1999, 19:7289-7304.
102. Abulrob A., Giuseppin S., Andrade M.F., McDermid A., Moreno M., Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 2004, 23:6967-6979.
103. Parat M.O., Riggins G.J. Caveolin-1, caveolae, and glioblastoma. Neuro Oncol. 2012, 14:679-688.
104. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
105. Vasudevan S. Functional validation of microRNA-target RNA interactions. Methods 2012, 58:126-134.
106. Harfe B.D. MicroRNAs in vertebrate development. Curr. Opin. Genet. Dev. 2005, 15:410-415.
107. Gurtan A.M., Sharp P.A. The role of miRNAs regulating gene expression. J. Mol. Biol. 2013, 425:3582-3600.
108. Reshmi G., Pillai M.R. Interplay Between HPV Oncoproteins and MicroRNAs in Cervical Cancer. Human Papillomavirus and Related Diseases-From Bench to Bedside-Research aspects 2012, 349-356. InTech. D.V. Broeck (Ed.).
109. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
110. Negrini M., Nicoloso M.S., Calin G.A. MicroRNAs and cancer-new paradigms in molecular oncology. Curr. Opin. Cell Biol. 2009, 21:470-479.
111. Martinez I., Gardiner A.S., Board K.F., Monzon F.A., Edwards R.P., Khan S.A. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008, 27:2575-2582.
112. Wang X., Tang S., Le S.Y., Lu R., Rader J.S., Meyers C., Zheng Z.M. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3:e2557.
113. Li B., Hu Y., Ye F., Li Y., Lv W., Xie X. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int. J. Gynecol. Cancer 2010, 20:597-604.
114. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
115. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26:731-743.
116. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
117. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. 2007, 104:15472-15477.
118. Yao T. Lin, MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20. Biochim. Biophys. Acta 2012, 1822:248-260.
119. Melar-New M., Laimins A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J. Virol. 2010, 84:5212-5221.
120. Stoler M.H., Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001, 285:1500-1505.
121. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., Szarewski A., Birembaut P., Kulasingam S., Sasieni P., Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 2006, 119:1095-1101.
122. Schiffman M., Wentzensen N. From human papillomavirus to cervical cancer. Obstet. Gynecol. 2010, 116:177-185.
123. Wentzensen N., Schwartz L., Zuna R.E., Smith K., Mathews C., Gold M.A., Allen R.A., Zang R., Dunn S.T., Walker J.L., Schiffman M. Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population. Clin. Cancer Res. 2012, 18:4154-4162.
124. Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papilloma-virus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 2005, 97:1066-1071.
125. Walker J.L., Wang S.S., Schiffman M.H., Solomon D. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am. J. Obstet. Gynecol. 2006, 195:341-348.
126. Ogilvie G.S., Krajden M., van Niekerk D.J., Martin R.E., Ehlen T.G., Ceballos K., Smith L.W., Kan L., Cook D.A., Peacock S., Stuart G.C., Franco E.L., Coldman A.J. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br. J. Cancer 2012, 107:1917-1924.
127. Clifford M., Smith J.S., Plummer M., Muñoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 2003, 88:63-73.
128. Termini L., Lina Villa L. Biomarcadores na triagem do câncer do colo uterino/Biomarkers in cervical cancer screening DST. J. bras Doenças Sex Transm. 2008, 20:125-131.
129. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 2004, 4:46-54.
130. Freeman H., Wingrove B. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities 2005, National Cancer Institute, Rockville, MD.
131. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford R,.G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int. J. Cancer 2007, 121:621-632.
132. Tsoumpou I., Arbyn M., Kyrgiou M., Went-zensen N., Koliopoulos G., Hirsch P.M., Mitsi V.M., Paraskevaidis E. p16 INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat. Rev. 2009, 35:210-220.
133. Huang M.Z., Huang S., Li D.Q., Nie X.M., Li H.B., Jiang X.M. The study of the combination detection of HPV-DNA and p16INK4a in cervical Lesions. Med. Oncol. 2011, 28:S547-S552.
134. Cheah P.L., Looi L.M., Teoh K.H., Mun K.S., Nazarina A.R. p16(INK4a) is a useful marker of human papillomavirus integration allowing risk stratification for cervical malignancies. Asian Pac. J. Cancer Prev. 2012, 13:469-472.
135. Rosamilia C., Feichter G., Tzankov A., Obermann E.C. Diagnosis and grading of cervical intraepithelial neoplasias. Pathologe 2012, 33:118-123.
136. INK4a immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: comparison study with HPV genotyping. J. Gynecol. Oncol. 2013, 24:215-221.
137. Portari E.A., Russomano F.B., de Camargo M.J., Machado Gayer C.R., da Rocha Guillobel H.C., Santos-Rebouças C.B., Brito Macedo J.M. Immunohistochemical Expression of Cyclin D1, p16Ink4a, p21WAF1, and Ki-67 Correlates With the Severity of Cervical Neoplasia. Int. J. Gynecol. Pathol. 2013, 32:501-508.
138. Roelens J., Reuschenbach M., Doeberitz M.V.K., Wentzensen N., Bergeron C., Arbyn M. p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities: a systematic review and meta-analysis. Cancer Cytopathol. 2012, 120:294-307.
139. Gustinucci D., Passamonti B., Cesarini E., Butera D., Palmieri E.A., Bulletti S., Carlani A., Staiano M., D'Amico M.R., D'Angelo V., Di Dato E., Martinelli N., Malaspina M., Spita N., Tintori B., Fulciniti F. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program. Acta Cytol. 2012, 56:506-514.
140. Samir R., Asplund A., Tot T., Pekar G., Hellberg D. High-risk HPV infection and CIN grade correlates to the expression of c-myc, CD4+, FHIT, E-cadherin, Ki-67, and p16INK4a. J. Low Genit. Tract Dis. 2011, 15:280-286.
141. Hidalgo J.V., Rocher A.E., López J.L., Gamboni M., Vighi S., Canessa O.E., Peressini S., Guerra F., di Carlo M.B., Palaoro L.A., Tatti S.A. AgNOR, p16 and human papillomavirus in low-grade squamous intra-epithelial lesions of the uterine cervix. Preliminary report. Biotech. Histochem. 2012, 87:257-264.
142. van Bogaert L.J. P16INK4a imunocytochemistry/immunohistochemistry: need for scoring uniformization to be clinically useful in gynecological pathology. Ann. Diagn. Pathol. 2012, 16:422-426.
143. Quint K.D., Koning M.N., Quint W.G., Pirog E.C. Progression of cervical low grade squamous intraepithelial lesions: in search of prognostic biomarkers. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, S0301-2115:00319-9.
144. Kim Y.T., Zhao M. Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med. J. 2005, 46:597-613.
145. Kalof A.N., Cooper K. p16INK4a immunoexpression: Surrogate markerof high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv. Anat. Pathol. 2006, 13:190-194.
146. Boulet G.A., Horvath C.A., Depuydt C.E., Bogers J.J. Biomarkers in cervical screening: quantitative reverse transcriptase PCR analysis of P16INK4a expression. Eur. J. Cancer Prev. 2010, 19:35-41.
147. 4a and p14ARF mRNA expression in Pap smears is age-related. Mod. Pathol. 2012, 25:465-470.
148. Omori M., Hashi A., Nakazawa K., Yuminamochi T., Yamane T., Hirara S., Katoh R., Hoshi K. Estimation of prognoses for Cervical Intraepithelial Neoplasia 2 by p16INK4a immunoexpression and High-Risk HPV In Situ Hybridization signal types. Am. J. Clin. Pathol. 2007, 128:208-217.
149. Negri G., Bellisano G., Carico E., Faa G., Kasal A., Antoniazzi S., Egarter-Vigl E., Piccin A., Dalla Palma P., Vittadello F. Usefulness of p16INK4a, ProEX C, and Ki-67 for the diagnosis of glandular dysplasia and adenocarcinoma of the cervix uteri. Int. J. Gynecol. Pathol. 2011, 30:407-413.
150. Ozaki S., Zen Y., Inoue M. Biomarker expression in cervical intraepithelial neoplasia: potential progression predictive factors for low-grade lesions. Hum. Pathol. 2011, 42:1007-1012.
151. Izadi-Mood N., Asadi K., Shojaei H., Sarmadi S., Ahmadi S.A., Sani S., Chelav Potential L.H. diagnostic value of P16 expression in premalignant and malignant cervical lesions. J. Res. Med Sci. 2012, 17:428-433.
152. Schluter C., Duchrow M., Wohlenberg C., Becker M.H., Key G., Flad H.D., Gerdes J. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J. Cell Biol. 1993, 123:513-522.
153. Kruse A.J., Baak J.P., de Bruin P.C., Jiwa M., Snijders W.P., Boodt P.J., Fons G., Houben P.W. The HS Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J. Pathol. 2001, 193:48-54.
154. Kruse A.J., Baak J.P.A., Janssen E.A., Bol M.G., Kjellevold K.H., Fianne B., Lovslett K., Bergh J. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immunouantitative variables. J. Pathol. 2003, 199:462-470.
155. Panjkovic M., Ivkovic-Kapicl T. Ki-67 expression in squamous intraepithelial lesions of the uterine cervix Arch. Oncol. 2006, 14:23-25.
156. Conesa-Zamora P., Doménech-Peris A., Orantes-Casado F.J., Ortiz-Reina S., Sahuquillo-Frías L., Acosta-Ortega J., García-Solano J., Pérez-Guillermo M. Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am. J. Clin. Pathol. 2009, 132:378-390.
157. Galgano M.T., Castle P.E., Atkins K.A., Brix W.K., Nassau S.R., Stoler M.H. Using Biomarkers as Objective Standards in the Diagnosis of Cervical Biopsies. Am. J. Surg. Pathol. 2010, 34:1077-1087.
158. Mimica M., Tomić S., Kardum G., Hofman I.D., Kaliterna V., Pejković L. Ki-67 quantitative evaluation as a marker of cervical intraepithelial neoplasia and human papillomavirus infection. Int. J. Gynecol. Cancer 2010, 20:116-119.
159. Kruse A.J., Baak J.P., de Bruin P.C., van de Goot F.R., Kurten N. Relationship between the presence of oncogenic HPV DNA assessed by polymerase chain reaction and Ki-67 immunoquantitative features in cervical intraepithelial neoplasia. J. Pathol. 2001, 195:557-562.
160. Pirog E.C., Baergen R.N., Soslow R.A., Tam D., DeMattia A.E., Chen Y.T.M.D., Isacson C.M.D. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with Ki-67 immunostaining. Am. J. Surg. Pathol. 2002, 26:70-75.
161. Sahebali S., Depuydt C.E., Segers K., Vereecken A.J., Van Marck E., Bogers J.J. Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool?. J. Clin. Pathol. 2003, 56:681-686.
162. Kruse A.J., Buhr-Wildhagen S., Janssen E.A., Baak J.P. The relationship between syntactic structure analysis features, histological grade and high-risk HPV DNA in cervical intraepithelial neoplasia. Cell. Oncol. 2004, 26:135-141.
163. Kruse A.J., Gudlaugsson E., Helliesen T., Janssen E.A., van Diermen B., Sandvik S., Baak J.P. Evaluation of prospective, routine application of Ki-67 immunoquantitation in early CIN for assessment of short-term progression risk. Anal. Quant. Cytol. Histol. 2004, 26:134-140.
164. Donà M.G., Vocaturo A., Giuliani M., Ronchetti L., Rollo F., Pescarmona E., Carosi M., Vocaturo G., Benevolo M. p16/Ki-67 dual staining in cervico-vaginal cytology: correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy. Gynecol. Oncol. 2012, 126:198-202.
165. Schmidt D., Bergeron C., Denton K.J., Ridder R. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011, 119:158-166.
166. Petry K.U., Schmidt D., Scherbring S., Luyten A., Reinecke-Lüthge A., Bergeron C., Kommoss F., Löning T., Ordi J., Regauer S., Ridder R. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol. Oncol. 2011, 121:505-509.
167. Singh M., Mockler D., Akalin A., Burke S., Shroyer A., Shroyer K.R. Immunocytochemical colocalization of P16(INK4a) and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma. Cancer Cytopathol. 2012, 120:26-34.
168. Rokita W., Skawiński D., Zmelonek-Znamirowska A., Kedzia W., Karowicz-Bilińska A., Spaczyński R., Spaczyński M. Results of pap smears and immunocytochemical detection of the p16 and Ki67 proteins in women with cervical intraepithelial neoplasia and cervical cancer. Ginekol. Pol. 2012, 83:822-826.
169. Yu L., Wang L., Zhong J., Chen S. Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol. 2010, 118:47-55.
170. Samarawardana P., Singh M., Shroyer K.R. Dual stain immunohistochemical localization of p16INK4A and ki-67: a synergistic approach to identify clinically significant cervical mucosal lesions. Appl. Immunohistochem. Mol. Morphol. 2011, 19:514-518.
171. Gertych A., Joseph A.O., Walts A.E., Bose S. Automated detection of dual p16/Ki67 nuclear immunoreactivity in liquid-based Pap tests for improved cervical cancer risk stratification. Ann. Biomed. Eng. 2012, 40:1192-1204.
172. Badr R.E., Walts A.E., Chung F., Bose S. BDProExC: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am. J. Surg. Pathol. 2008, 32:899-906.
173. Depuydt C.E., Makar A.P., Ruymbeke M.J., Benoy I.H., Vereecken A.J., Bogers J.J. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiol. Biomarkers Prev. 2011, 20:628-637.
174. Shroyer K.R., Homer P., Heinz D., Singh M. Validation of a novel immunocytochemical assay for topoisomerase II-α and minichromosome maintenance protein 2 expression incervical cytology. Cancer 2006, 108:324-330.
175. Kelly D., Kincaid E., Fansler Z., Rosenthal D.L., Clark D.P. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples using a novel immunocytochemical assay. Cancer 2006, 108:494-500.
176. Tambouret R.H., Misdraji J., Wilbur D.C. Longitudinal clinical evaluation of a novel antibody cocktail for detection of high-grade squamous intraepithelial lesions on cervical cytology specimens. Arch. Pathol. Lab. Med. 2008, 132:918-925.
177. Alaghehbandan R., Fontaine D., Bentley J., Escott N., Ghatage P., Lear A., Coutlee F., Ratnam S. Performance of proex c and pretect hpv-proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 hpv dna test for triaging ASCUS and LSIL cytology. Diagn. Cytopathol. 2013, 41:767-775.
178. Siddiqui M.T., Hornaman K., Cohen C., Nassar A. ProEx C immunocytochemistry and high-risk human papillomavirus DNA testing in papanicolaou tests with atypical squamous cell (ASC-US) cytology: correlation study with histologic biopsy. Arch. Pathol. Lab. Med. 2008, 132:1648-1652.
179. Aximu D., Azad A., Ni R., Colgan T., Nanji S. A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-α and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int. J. Gynecol. Pathol. 2009, 28:114-119.
180. Goto T., Takano M., Sasa H., Tsuda H., Yamau-chi K., Kikuchi Y. Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia. Oncol. Rep. 2006, 15:387-391.
181. Micalessi M.I., Boulet G., Pintelon I., Verstraelen P., Nauwelaers F., Ryser M., Bogers J. High-Content Imaging in Cervical Cancer Screening. J. Biomol. Screen. 2013, 18(1):135-142.
182. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37:S9-S15.
183. Kim G.E., Kim Y.B., Cho N.H., Chung H.C., Pyo H.R., Lee J.D., Park T.K., Koom W.S., Chun M., Suh C.O. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin. Cancer Res. 2004, 10:1366-1374.
184. Movva S., Rodriguez L., Arias-Pulido H., Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer 2009, 115:3166-3180.
185. Soonthornthum T., Arias-Pulido H., Joste N., Lomo L., Muller C., Rutledge T., Verschraegen C. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann. Oncol. 2011, 22:2166-2178.
186. Balan R., Simion N., Giuşcǎ S.E., Grigoraş A., Gheucǎ-Solovǎstru L., Gheorghiţǎ V., Amǎlinei C., Cǎruntu I.D. Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions. Rom. J. Morphol. Embryol. 2011, 52:1187-1194.
187. Scambia G., Ferrandina G., Distefano M., D'Agostino G., Benedetti-Panici P., Mancuso S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett. 1998, 123:135-139.
188. Ngan H.Y., Cheung A.N., Liu S.S., Cheng D.K., Ng T.Y., Wong L.C. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol. 2001, 22:176-183.
189. Akerman G.S., Tolleson W.H., Brown K.L., Zyzak L.L., Mourateva E., Engin T.S., Basaraba A., Coker A.L., Creek K.E., Pirisi L. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res. 2001, 61:3837-3843.
190. Schrevel M., Gorter A., Kolkman-Uljee S.M., Trimbos J.B., Fleuren G.J., Jordanova E.S. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod. Pathol. 2011, 4:720-728.
191. Venuti A., Salani D., Manni V., Poggiali F., Bagnato A. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J. 2000, 14:2277-2283.
192. Bagnato A., Cirilli A., Salani D., Simeone P., Muller A., Nicotra M.R., Natali P.G., Venuti A. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res. 2002, 62:6381-6384.
193. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R., Albelda S.M. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 2005, 11:3974-3986.
194. Gartel A.L. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk. Res. 2005, 29:1237-1238.
195. Werness B.A., Wang H.Q., Chance J., Goldstein D.J. p53-independent expression of p21waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix. Mod. Pathol. 1997, 10:578-584.
196. Lu X., Toki T., Konishi I., Nikaido T., Fujii S. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer 1998, 82:2409-2417.
197. Skomedal H., Kristensen G.B., Lie A.K., Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol. Oncol. 1999, 73:223-228.
198. Lie A.K., Skarsvåg S., Skomedal H., Haugen O.A., Holm R. Expression of p53, MDM2, and p21 proteins in high-grade cervical intraepithelial neoplasia and relationship to human papillomavirus infection. Int. J. Gynecol. Pathol. 1999, 18:5-11.
199. Huang L.W., Chou Y.Y., Chao S.L., Chen T.J., Lee T.T. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol. Oncol. 2001, 83:348-354.
200. Giannoudis A., Herrington C.S. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 2000, 89:1300-1307.
201. Huang L.W., Chao S.L., Hwang J.L., Chou Y.Y. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol. Oncol. 2002, 85:524-528.
202. Sgambato A., Zannoni G.F., Faraglia B., Camerini A., Tarquini E., Spada D., Cittadini A. Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. Gynecol. Oncol. 2004, 92:776-783.
203. Bouda J., Hes O., Koprivova M., Pesek M., Svoboda T., Boudova L. P27 as a prognostic factor of early cervical carcinoma. Int. J. Gynecol. Cancer 2013, 23:164-169.
204. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:77-86.
205. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., Subbaramaiah K., Dannenberg A.J. Cyclooxy-genase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 2001, 7:429-434.
206. Kim J.Y., Lim S.J., Park K., Lee C.M., Kim J. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol. Oncol. 2005, 97:337-341.
207. Farley J.H., Truong V., Goo E., Uyehara C., Belnap C., Larsen W.I. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia. Gynecol. Oncol. 2006, 103:425-430.
208. Hefler L.A., Grimm C., Speiser P., Sliutz G., Reinthaller A. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III phase II trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006, 125:251-254.
209. Kim K., Jeon Y.T., Park I.A., Kim J.W., Park N.H., Kang S.B., Lee H.P., Song Y.S. Cyclooxygenase-2 expression in cervical intraepithelial neoplasia. Ann. N. Y. Acad. Sci. 2009, 1171:111-115.
210. Gaffney D.K., Holden J., Davis M., Zempolich K., Murphy K.J., Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:1213-1217.
211. Ferrandina G., Lauriola L., Distefano M.G., Zannoni G.F., Gessi M., Legge F., Maggiano N., Mancuso S., Capelli A., Scambia G., Ranelletti F.O. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J. Clin. Oncol. 2002, 20:973-981.
212. Saldivar J.S., Lopez D., Feldman R.A., Tharappel-Jacob R., de la Rosa A., Terreros D., Baldwin W.S. COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study. Gynecol. Oncol. 2007, 107:S155-S162.
213. Huang M., Chen Q., Xiao J., Liu C., Zhao X. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int. J. Cancer 2013, 132:363-373.
214. Paley P.J., Staskus K.A., Gebhard K., Mohanraj D., Twiggs L.B., Carson L.F., Ramakrishnan S. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997, 80:98-106.
215. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., Mori A., Onodera H., Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer 1998, 78:1379-1384.
216. Ohta Y., Tomita Y., Oda M., Watanabe S., Murakami S., Watanabe Y. Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann. Thorac. Surg. 1999, 68:1034-1038.
217. Cheng W.F., Chen C.A., Lee C.N., Wei L.H., Hsieh F.J., Hsieh C.Y. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet. Gynecol. 2000, 96:721-726.
218. Kim M.H., Seo S.S., Song Y.S., Kang D.H., Park I.A., Kang S.B., Lee H.P. Expression of cyclooxygenase-1 and-2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes. Gynecol. Oncol. 2003, 90:83-90.
219. Van Trappen P.O., Steele D., Lowe D.G., Baithun S., Beasley N., Thiele W., Weich H., Krishnan J., Shepherd J.H., Pepper M.S., Jackson D.G., Sleeman J.P., Jacobs I.J. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J. Pathol. 2003, 201:544-554.
220. Kang J.O., Hong S.E. The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone. J. Korean Med. Sci. 2004, 192:693-697.
221. Dai Y., Zhang X., Peng Y., Wang Z. The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol. Oncol. 2005, 97:96-103.
222. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357:2666-2676.
223. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
224. Branca M., Giorgi C., Santini D., Di Bonito L., Ciotti M., Benedetto A., Paba P., Costa S., Bonifacio D., Di Bonito P., Accardi L., Favalli C., Syrjänen K. HPV-Pathogen ISS Study Group, Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J. Clin. Pathol. 2006, 59:40-47.
225. Gadducci A., Guerrieri M.E., Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit. Rev. Oncol. Hematol. 2013, 86:104-129.
226. Zagouri F., Sergentanis T.N., Chrysikos D., Filipits M., Bartsch R. Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol. Oncol. 2012, 126:291-303.
227. Suprynowicz F.A., Disbrow G.L., Krawczyk E., Simic V., Lantzky K., Schlegel R. HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 2008, 27:1071-1078.
228. Sun J., Gao J., Hu J.B., Fan L.F., Zhu X.B., Subahan R., Chen H.L. Expression of Cav-1 in tumour cells, rather than in stromal tissue, may promote cervical squamous cell carcinoma proliferation, and correlates with high-risk HPV infection. Oncol. Rep. 2012, 27:1733-1740.
229. Lui W.O., Pourmand N., Patterson B.K., Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007, 67:6031-6043.
230. Hu X., Schwarz J.K., Lewis J.S., Huettner P.C., Rader J.S., Deasy J.O., Grigsby P.W., Wang X. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010, 70:441-448.
231. McBee W.C., Gardiner A.S., Edwards R.P., Lesnock J.L., Bhargava R., Austin R.M., Guido R.S., Khan S.A. MicroRNA Analysis in Human Papillomavirus (HPV)-Associated Cervical Neoplasia and Cancer. J. Carcinog. Mutagen. 2011, 5(1):114.
232. Deftereos G., Corrie S.R., Feng Q., Morihara J., Stern J., Hawes S.E., Kiviat N.B. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One 2011, 6:e28423.
233. Liu L., Yu X., Guo X., Tian Z., Su M., Long Y., Huang C., Zhou F., Liu M., Wu X., Wang X. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol. Med. Rep. 2012, 5:753-760.
234. Vasilescu F., Ceauşu M., Tǎnase C., Stǎnculescu R., Vlǎdescu T., Ceauşu Z. P53, p63 and Ki-67 assessment in HPV-induced cervical neoplasia. Rom. J. Morphol. Embryol. 2009, 50:357-361.
235. Cheung A.N., Tsun K.L., Ng K.M., Szeto E., Siu M.K., Wong E.S., Ngan H.Y. P634A4 and TAp73 immunocytochemistry in liquid-based cervical cytology-potential biomarkers for diagnosis and progress prediction of cervical neoplasia. Mod. Pathol. 2010, 23:559-566.
236. Wong Y.F., Chung T.K., Wang V.W., Smith D.I. DNA microchips to identify molecular signatures in cervical cancers. Methods Mol. Biol. 2007, 385:87-101.
237. Szalmas A., Konya J. Epigenetic alterations in cervical carcinogenesis. Semin. Cancer Biol. 2009, 19:144-152.
238. Yang H.J., Liu V.W., Wang Y., Tsang P.C., Ngan H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 2006, 6:1-10.
239. Wentzensen N., von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis. Markers 2007, 23:315-330.
240. Yang H.J. Aberrant DNA methylation in cervical carcinogenesis. Chin. J. Cancer 2013, 32:42-48.
241. Lin C.J., Lai H.C., Wang K.H., Hsiung C.A., Liu H.W., Ding D.C., Hsieh C.Y., Chu T.Y. Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASCUS smear results. Am. J. Obstet. Gynecol. 2011, 204:21.e1-21.e7.
242. Chao T.K., Ke F.Y., Liao Y.P., Wang H.C., Yu C.P., Lai H.C. Triage of cervical cytological diagnoses of atypical squamous cells by DNA methylation of paired boxed gene 1 (PAX1). Diagn. Cytopathol. 2011, 41:41-46.
243. Eijsink J.J., Yang N., Lendvai A., Klip H.G., Volders H.H., Buikema H.J., van Hemel B.M., Voll M., Coelingh Bennink H.J., Schuuring E., Wisman G.B., van der Zee A.G. Detection of cervical neoplasia by DNA methylation analysis in cervico vaginal lavages, a feasibility study. Gynecol. Oncol. 2011, 120:280-283.
244. Overmeer R.M., Louwers J.A., Meijer C.J., van Kemenade F.J., Hesselink A.T., Daalmeijer N.F., Wilting S.M., Heideman D.A., Verheijen R.H., Zaal A., van Baal W.M., Berkhof J., Snijders P.J., Steenbergen R.D. Combined CADM1 and MAL promoter methylation analysis to detect (pre) malignant cervical lesions in high risk HPV positive women. Int. J. Cancer 2011, 129:2218-2225.
245. Botezatu A., Goia-Rusanu C.D., Iancu I.V., Huica I., Plesa A., Socolov D., Ungureanu C., Anton G. Quantitative analysis of the relationship between microRNA-124a, -34b and-203 gene methylation and cervical oncogenesis. Mol. Med. Rep. 2011, 4:121-128.
246. Heselmeyer K., Schrock E., du Manoir S., Blegen H., Shah K., Steinbeck R., Auer G., Ried T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:479-484.
247. Lando M., Wilting S.M., Snipstad K., Clancy T., Bierkens M., Aarnes E.K., Holden M., Stokke T., Sundfør K., Holm R., Kristensen G.B., Steenbergen R.D., Lyng H. Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J. Pathol. 2013, 230:59-69.
248. Senchenko V.N., Kisseljova N.P., Ivanova T.A., Dmitriev A.A., Krasnov G.S., Kudryavtseva A.V., Panasenko G.V., Tsitrin E.B., Lerman M.I., Kisseljov F.L., Kashuba V.I., Zabarovsky E.R. Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer. Epigenetics 2013, 8:59-69.
249. Heselmeyer-Haddad K., Sommerfeld K., White N.M., Chaudhri N., Morrison L.E., Palanisamy N., Wang Z.Y., Auer G., Steinberg W., Ried T. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am. J. Pathol. 2005, 166:1229-1238.
250. Andersson S., Sowjanya P., Wangsa D., Hjerpe A., Johansson B., Auer G., Gravitt P.E., Larsson C., Wallin K.L., Ried T., Heselmeyer-Haddad K. Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. Am. J. Pathol. 2009, 175:1831-1847.
251. Jalali G.R., Herzog T.J., Dziura B., Walat R., Kilpatrick M.W. Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. Am. J. Obstet. Gynecol. 2010, 202:581.e1-581.e5.
252. Ziegler A., Koch A., Krockenberger K., Grosshennig A. Personalized medicine using DNA biomarkers: a review. Hum. Genet. 2012, 131:1627-1638.
253. Freitas A.C., Gurgel A.P., Chagas B.S., Coimbra E.C., do Amaral C.M. Susceptibility to cervical cancer: an overview. Gynecol. Oncol. 2012, 126:304-311.
254. Chagas B.S., Batista M.V., Guimarães V., Balbino V.Q., Crovella S., Freitas A.C. New variants of E6 and E7 oncogenes of human papillomavirus type 31 identified in Northeastern Brazil. Gynecol. Oncol. 2011, 123:284-288.
255. Chagas B.S., Batista M.V., Crovella S., Gurgel A.P., Silva Neto J.D., Serra I.G., Amaral C.M., Balbino V.Q., Muniz M.T., Freitas A.C. Novel E6 and E7 oncogenes variants of Human Papillomavirus Type 31 in Brazilian Women with Abnormal Cervical Cytology. Infect. Genet. Evol. 2013, 10:13-18.